SCHEMBL580283

SCHEMBL580283

[CH2]CC(O)C[CH2]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9764158 0.79
SCHEMBL94889 0.79
SCHEMBL25338321 0.79
SCHEMBL245364 0.76
SCHEMBL31194 0.76
SCHEMBL28914755 0.76
SCHEMBL2589777 0.76
SCHEMBL10747765 0.76
SCHEMBL9139875 0.76
SCHEMBL8594077 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240238303-A1 LARGE-CONDUCTANCE POTASSIUM CHANNEL MODULATORS, COMPOSITIONS THEREOF, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF ENALARE THERAPEUTICS INC (US) 2024-07-18 US claimed
EP-4333852-A1 LARGE-CONDUCTANCE POTASSIUM CHANNEL MODULATORS, COMPOSITIONS THEREOF, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF Enalare Therapeutics Inc. (US) 2024-03-13 EP claimed
CN-117479945-A Large conductance potassium channel modulators, compositions thereof, methods of making and methods of using the same 依那拉治疗股份有限公司 2024-01-30 CN claimed
WO-2023250141-A2 METHODS OF TREATING NEUROLOGICAL VENTILATORY INSUFFICIENCY ENALARE THERAPEUTICS INC. (US) 2023-12-28 WO claimed
US-20230414624-A1 METHODS OF TREATING NEUROLOGICAL VENTILATORY INSUFFICIENCY ENALARE THERAPEUTICS INC (US) 2023-12-28 US claimed
WO-2023225177-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT RESPIRATORY DEPRESSION IN PATIENTS ENALARE THERAPEUTICS INC. (US) 2023-11-23 WO claimed
WO-2023192602-A2 RESPIRATORY STIMULANT NASAL FORMULATIONS ENALARE THERAPEUTICS INC. (US) 2023-10-05 WO claimed
US-20230310440-A1 RESPIRATORY STIMULANT NASAL FORMULATIONS ENALARE THERAPEUTICS INC. 2023-10-05 US claimed
US-20230210857-A1 RESPIRATORY STIMULANT PARENTERAL FORMULATIONS ENALARE THERAPEUTICS INC. 2023-07-06 US claimed
WO-2023081185-A1 METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT ENALARE THERAPEUTICS INC. (US) 2023-05-11 WO claimed
US-20120295911-A1 Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases GALLEON PHARMACEUTICALS, INC. 2012-11-22 US claimed
WO-2012074999-A1 NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES GALLEON PHARMACEUTICALS, INC. (US) 2012-06-07 WO claimed
US-20120142647-A1 Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases GALLEON PHARMACEUTICALS, INC. 2012-06-07 US claimed
EP-0929553-B1 PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF NOVARTIS AG (CH) 2005-03-16 EP claimed
US-6767906-B2 INHIBIT P34CDC2/CYCLIN BCDC13 KINASE AND PROTEIN TYROSINE KINASE PP60C-SRC AND CAN BE USED FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES, FOR EXAMPLE CHEMOTHERAPY OF TUMOURS OR OSTEOPOROSIS. NOVARTIS AG (CH) 2004-07-27 US claimed
US-6251911-B1 Pyrimidine derivatives and processes for the preparation thereof NOVARTIS AG (CH) 2001-06-26 US claimed
EP-0929553-A1 PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF Novartis AG (CH) 1999-07-21 EP claimed
WO-1998014450-A1 PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF NOVARTIS AG (CH) 1998-04-09 WO claimed
US-4683228-A Guanidinopyrazolylamides, guanidimoimidazolylamides, compositions containing them, and method of using them to inhibit gastric acid secretion ICI AMERICAS INC. (US) 1987-07-28 US claimed
EP-0150099-A1 Guanidine derivatives IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1985-07-31 EP claimed